Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 687-kidney-and-urinary-tract-neoplasms-with-cc
    Ask Trek AI about this page

    Kidney and Urinary Tract Neoplasms with CC: Inpatient Reimbursement Overview

    DRG 687 covers kidney and urinary tract neoplasms with a Complication or Comorbidity, encompassing inpatient care for renal, ureteral, and bladder tumors that require additional resources. This Diagnosis-Related Group matters for inpatient reimbursement because the presence of a Complication or Comorbidity increases payment relative to non-Complication or Comorbidity cases to reflect higher expected resource use.

    Customize your policy alerts

    Sign up for drg 687 policy alerts

    Get alerted when payer policies referencing 687 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 687 Overview

    DRG 687 covers inpatient admissions for kidney and urinary tract neoplasms with a Complication or Comorbidity present, including surgical and nonsurgical management of renal, ureteral, and bladder tumors when an associated complication or comorbidity affects care. This Diagnosis-Related Group groups cases with increased resource use compared with non-Complication or Comorbidity cases, influencing Medicare payment by adjusting relative weight for greater clinical complexity. Typical services include tumor resections, nephrectomy procedures, endoscopic interventions, and perioperative medical management tied to the neoplasm and the Complication or Comorbidity. Accurate clinical documentation and coding of the neoplasm type and any Complication or Comorbidity are essential for appropriate inpatient reimbursement under Medicare.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative and surgical technique trials assessing nephron-sparing surgery versus radical nephrectomy in patients with localized kidney tumors and comorbid conditions: these studies enroll inpatients with kidney neoplasms who face competing risks from chronic kidney disease, diabetes, or cardiovascular disease to compare short-term surgical morbidity, length of stay, blood loss, and early renal function outcomes. They address which operative approach minimizes inpatient complications and resource use, directly informing hospital care pathways and reimbursement considerations for patients classified under this DRG.
    • Neoadjuvant and adjuvant therapy feasibility and sequencing studies in patients with high-risk or locally advanced urinary tract neoplasms undergoing inpatient surgical care: trials in this category examine timing, tolerability, and perioperative safety of systemic therapies given before or after definitive surgery in patients with comorbidities that complicate inpatient management. Findings help providers optimize inpatient timing of systemic treatments relative to surgery and guide payers on expected inpatient resource utilization and readmission risk associated with multimodal care.
    • Post-discharge outcomes, surveillance, and care coordination studies focused on renal function preservation and readmission prevention for patients after inpatient treatment for kidney and urinary tract neoplasms: these observational and interventional studies enroll patients discharged after nephrectomy or urinary tract surgery to evaluate care transitions, outpatient surveillance strategies, and interventions (e.g., early nephrology follow-up, medication reconciliation) that reduce 30- and 90-day readmissions, progression to end-stage renal disease, and unplanned costs. This research is relevant to hospitals and payers because improvements in post-discharge management can lower avoidable inpatient utilization, improve long-term costs, and enhance risk adjustment for patients in this DRG.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.